| 335 | Humans |
| 183 | Coronavirus Infections (epidemiology) |
| 178 | Pneumonia, Viral (epidemiology) |
| 128 | Coronavirus Infections (transmission) |
| 126 | Pneumonia, Viral (transmission) |
| 92 | Betacoronavirus |
| 87 | Coronavirus Infections (diagnosis) |
| 85 | Disease Outbreaks |
| 82 | Pneumonia, Viral (diagnosis) |
| 79 | China (epidemiology) |
| 70 | Coronavirus Infections (prevention & control) |
| 67 | Pneumonia, Viral (prevention & control) |
| 67 | China |
| 64 | Betacoronavirus (pathogenicity) |
| 56 | Betacoronavirus (isolation & purification) |
| 52 | Female |
| 51 | Betacoronavirus (genetics) |
| 50 | Male |
| 47 | Adult |
| 45 | Middle Aged |
| 43 | Animals |
| 41 | Pneumonia, Viral (complications) |
| 40 | Travel |
| 40 | Coronavirus Infections (complications) |
| 39 | Coronavirus Infections (virology) |
| 36 | Pneumonia, Viral (virology) |
| 35 | Coronavirus Infections (therapy) |
| 34 | Pneumonia, Viral (therapy) |
| 32 | Public Health |
| 32 | Pandemics |
| 26 | Aged |
| 24 | Pneumonia, Viral (drug therapy) |
| 23 | Phylogeny |
| 23 | Lung (diagnostic imaging) |
| 23 | Global Health |
| 22 | Genome, Viral |
| 22 | Coronavirus Infections (drug therapy) |
| 21 | Young Adult |
| 21 | Coronavirus Infections |
| 20 | Tomography, X-Ray Computed |
| 20 | Pneumonia, Viral (diagnostic imaging) |
| 19 | Disease Outbreaks (prevention & control) |
| 19 | Coronavirus Infections (diagnostic imaging) |
| 19 | Child |
| 18 | Pneumonia, Viral |
| 18 | Fever (etiology) |
| 18 | Antiviral Agents (therapeutic use) |
| 17 | Pneumonia, Viral (pathology) |
| 17 | Coronavirus Infections (pathology) |
| 15 | Risk Factors |
| 15 | Retrospective Studies |
| 15 | Radiography, Thoracic |
| 15 | Coronavirus |
| 14 | World Health Organization |
| 14 | Lung (pathology) |
| 14 | Adolescent |
| 13 | Zoonoses |
| 13 | Population Surveillance |
| 13 | Cough (etiology) |
| 13 | Chiroptera (virology) |
| 12 | SARS Virus (pathogenicity) |
| 11 | Practice Guidelines as Topic |
| 11 | Pneumonia, Viral (etiology) |
| 11 | Epidemics |
| 11 | Betacoronavirus (physiology) |
| 10 | Severe Acute Respiratory Syndrome (epidemiology) |
| 10 | Republic of Korea |
| 10 | Pneumonia, Viral (psychology) |
| 10 | Pneumonia, Viral (mortality) |
| 10 | Pandemics (prevention & control) |
| 10 | Infection Control |
| 10 | Europe (epidemiology) |
| 10 | Coronavirus Infections (psychology) |
| 10 | Coronavirus Infections (mortality) |
| 10 | Contact Tracing |
| 10 | Betacoronavirus (drug effects) |
| 10 | Aged, 80 and over |
| 9 | United States (epidemiology) |
| 9 | Time Factors |
| 9 | Severity of Illness Index |
| 9 | SARS Virus (genetics) |
| 9 | Real-Time Polymerase Chain Reaction |
| 9 | Patient Isolation |
| 9 | Infection Control (methods) |
| 9 | Infant |
| 9 | Civil Defense |
| 8 | Severe Acute Respiratory Syndrome (virology) |
| 8 | SARS Virus |
| 8 | Risk Assessment |
| 8 | Models, Theoretical |
| 8 | Information Dissemination |
| 8 | Health Personnel |
| 8 | Child, Preschool |
| 7 | United States |
| 7 | Respiration, Artificial |
| 7 | Prognosis |
| 7 | Internationality |
| 7 | Health Planning |
| 7 | Dyspnea (etiology) |
| 7 | Communication |
| 7 | Australia (epidemiology) |
| 6 | Severe Acute Respiratory Syndrome (transmission) |
| 6 | Ritonavir (therapeutic use) |
| 6 | Quarantine |
| 6 | Middle East Respiratory Syndrome Coronavirus |
| 6 | Middle East Respiratory Syndrome Coronavirus (pathogenicity) |
| 6 | Mental Health Services |
| 6 | Mass Screening |
| 6 | Lopinavir (therapeutic use) |
| 6 | Infectious Disease Incubation Period |
| 6 | Forecasting |
| 6 | Emergencies |
| 6 | Disease Susceptibility |
| 6 | Disease Progression |
| 6 | Coronavirus Infections (veterinary) |
| 6 | Communicable Diseases, Emerging |
| 6 | Communicable Diseases, Emerging (virology) |
| 6 | Betacoronavirus (immunology) |
| 6 | Betacoronavirus (classification) |
| 6 | Air Travel |
| 5 | Virus Replication |
| 5 | Viral Load |
| 5 | Travel Medicine |
| 5 | Social Conditions |
| 5 | Reverse Transcriptase Polymerase Chain Reaction |
| 5 | Republic of Korea (epidemiology) |
| 5 | RNA, Viral (genetics) |
| 5 | Public Health Surveillance |
| 5 | Pregnancy |
| 5 | Pneumonia |
| 5 | Pneumonia, Viral (veterinary) |
| 5 | Medical History Taking |
| 5 | Infectious Disease Transmission, Patient-to-Professional |
| 5 | Infant, Newborn |
| 5 | Health Services Accessibility |
| 5 | Fatigue (etiology) |
| 5 | Family Health |
| 5 | Disease Transmission, Infectious |
| 5 | Disaster Planning |
| 5 | Diagnosis, Differential |
| 5 | Delivery of Health Care |
| 5 | Coronavirus (genetics) |
| 5 | Comorbidity |
| 5 | Communicable Diseases, Emerging (epidemiology) |
| 5 | Clinical Trials as Topic |
| 5 | Betacoronavirus (metabolism) |
| 5 | Antiviral Agents (pharmacology) |
| 5 | Amino Acid Sequence |
| 5 | Alanine (analogs & derivatives) |
| 4 | coronavirus |
| 4 | Zoonoses (virology) |
| 4 | Zoonoses (transmission) |
| 4 | Vulnerable Populations |
| 4 | Viral Vaccines (immunology) |
| 4 | United Kingdom (epidemiology) |
| 4 | Uncertainty |
| 4 | Taiwan |
| 4 | Spike Glycoprotein, Coronavirus (genetics) |
| 4 | Spike Glycoprotein, Coronavirus (chemistry) |
| 4 | Severe Acute Respiratory Syndrome |
| 4 | Severe Acute Respiratory Syndrome (pathology) |
| 4 | Sequence Alignment |
| 4 | Sensitivity and Specificity |
| 4 | Seasons |
| 4 | Respiratory Distress Syndrome, Adult (virology) |
| 4 | Protein Structure, Tertiary |
| 4 | Politics |
| 4 | Pneumonia, Viral (immunology) |
| 4 | Pneumonia, Viral (genetics) |
| 4 | Personal Protective Equipment |
| 4 | Peptidyl-Dipeptidase A (physiology) |
| 4 | Peptidyl-Dipeptidase A (metabolism) |
| 4 | Patient Care Planning |
| 4 | Mortality |
| 4 | Middle East Respiratory Syndrome Coronavirus (genetics) |
| 4 | Mental Health |
| 4 | Italy (epidemiology) |
| 4 | Interprofessional Relations |
| 4 | Incidence |
| 4 | Hospitalization |
| 4 | Guidelines as Topic |
| 4 | Drug Repositioning |
| 4 | Drug Evaluation, Preclinical |
| 4 | Drug Discovery |
| 4 | Drug Combinations |
| 4 | Disease Reservoirs |
| 4 | Disease Reservoirs (virology) |
| 4 | Cross Infection (prevention & control) |
| 4 | Coronavirus Infections (immunology) |
| 4 | Coronavirus Infections (genetics) |
| 4 | Coronavirus (isolation & purification) |
| 4 | Colorectal Neoplasms (complications) |
| 4 | Biomedical Research |
| 4 | Betacoronavirus (chemistry) |
| 4 | Anxiety |
| 4 | Alanine (therapeutic use) |
| 4 | Age Factors |
| 4 | Age Distribution |
| 4 | Access to Information |
| 3 | Zoonoses (epidemiology) |
| 3 | World Health Organization (organization & administration) |
| 3 | Viral Proteins (genetics) |
| 3 | Viral Proteins (chemistry) |
| 3 | Universities |
| 3 | United Kingdom |
| 3 | Thailand |
| 3 | Surveys and Questionnaires |
| 3 | Stress, Psychological |
| 3 | Spike Glycoprotein, Coronavirus (immunology) |
| 3 | Singapore (epidemiology) |
| 3 | Ships |
| 3 | Severe Acute Respiratory Syndrome (drug therapy) |
| 3 | Severe Acute Respiratory Syndrome (diagnostic imaging) |
| 3 | Severe Acute Respiratory Syndrome (diagnosis) |
| 3 | Science (organization & administration) |
| 3 | SARS Virus (immunology) |
| 3 | SARS Virus (drug effects) |
| 3 | Risk |
| 3 | Public Health Practice |
| 3 | Public Health (methods) |
| 3 | Protective Clothing |
| 3 | Periodicals as Topic |
| 3 | Pandemics (statistics & numerical data) |
| 3 | Occupational Exposure |
| 3 | Models, Genetic |
| 3 | Middle East Respiratory Syndrome Coronavirus (drug effects) |
| 3 | Melia azedarach |
| 3 | Mass Screening (methods) |
| 3 | Internet |
| 3 | Intensive Care Units |
| 3 | Infectious Disease Transmission, Vertical |
| 3 | Infections |
| 3 | Hygiene |
| 3 | Host-Pathogen Interactions |
| 3 | Host Specificity |
| 3 | Health Policy |
| 3 | Genome, Viral (genetics) |
| 3 | Fever (virology) |
| 3 | Evidence-Based Medicine |
| 3 | Emigration and Immigration |
| 3 | Drug Design |
| 3 | Disease Transmission, Infectious (prevention & control) |
| 3 | Disease Reservoirs (veterinary) |
| 3 | Delivery of Health Care (trends) |
| 3 | Databases, Genetic |
| 3 | Cytochrome P-450 CYP3A Inhibitors (therapeutic use) |
| 3 | Cross-Sectional Studies |
| 3 | Critical Illness (therapy) |
| 3 | Critical Care |
| 3 | Cough (virology) |
| 3 | Coronavirus (pathogenicity) |
| 3 | Consensus |
| 3 | Communicable Disease Control |
| 3 | Chiroptera |
| 3 | COVID-19 |
| 3 | Betacoronavirus (growth & development) |
| 3 | Basic Reproduction Number |
| 3 | Asymptomatic Infections |
| 3 | Asymptomatic Diseases |
| 3 | Antiviral Agents (chemistry) |
| 3 | Antibodies, Monoclonal (therapeutic use) |
| 3 | Adaptation, Psychological |
| 2 | financial volatility |
| 2 | Whole Genome Sequencing |
| 2 | Virus Shedding |
| 2 | Virus Diseases (transmission) |
| 2 | Virus Diseases (epidemiology) |
| 2 | Virulence |
| 2 | Viral Vaccines (therapeutic use) |
| 2 | Viral Proteins |
| 2 | Viral Envelope Proteins (analysis) |
| 2 | Vero Cells |
| 2 | Vaccines |
| 2 | Travel-Related Illness |
| 2 | Travel (legislation & jurisprudence) |
| 2 | Transportation |
| 2 | Telemedicine |
| 2 | State Medicine |
| 2 | Spike Glycoprotein, Coronavirus (metabolism) |
| 2 | Social Support |
| 2 | Social Media |
| 2 | Sex Distribution |
| 2 | Severe Acute Respiratory Syndrome (therapy) |
| 2 | Sequence Analysis, Protein |
| 2 | Science (economics) |
| 2 | SARS Virus (physiology) |
| 2 | SARS Virus (classification) |
| 2 | SARS Virus (chemistry) |
| 2 | Rural Population |
| 2 | Ritonavir |
| 2 | Ribonucleotides (therapeutic use) |
| 2 | Respiratory Tract Infections (epidemiology) |
| 2 | Respiratory Sounds |
| 2 | Respiratory Insufficiency |
| 2 | Respiratory Insufficiency (virology) |
| 2 | Respiratory Insufficiency (therapy) |
| 2 | Respiratory Distress Syndrome, Adult (therapy) |
| 2 | Research |
| 2 | Recombination, Genetic |
| 2 | Recombinant Proteins (therapeutic use) |
| 2 | Receptors, Virus (chemistry) |
| 2 | Racism |
| 2 | Public Policy |
| 2 | Proteome |
| 2 | Prevalence |
| 2 | Pregnancy Outcome |
| 2 | Pregnancy Complications, Infectious (prevention & control) |
| 2 | Pregnancy Complications, Infectious (diagnosis) |
| 2 | Predictive Value of Tests |
| 2 | Population Surveillance (methods) |
| 2 | Pneumonia, Viral (metabolism) |
| 2 | Pneumonia (etiology) |
| 2 | Pneumonia (diagnosis) |
| 2 | Pharynx (virology) |
| 2 | Pharyngitis (etiology) |
| 2 | Peptidyl-Dipeptidase A (drug effects) |
| 2 | Patient Safety |
| 2 | Patient Education as Topic |
| 2 | Patient Discharge |
| 2 | Patient Care |
| 2 | Nucleosides (therapeutic use) |
| 2 | Nucleocapsid Proteins (genetics) |
| 2 | Nucleocapsid Proteins (chemistry) |
| 2 | Nucleic Acid Amplification Techniques |
| 2 | Noninvasive Ventilation |
| 2 | New Zealand |
| 2 | Myalgia (etiology) |
| 2 | Myalgia (epidemiology) |
| 2 | Mutation Rate |
| 2 | Mortality (trends) |
| 2 | Models, Statistical |
| 2 | Models, Molecular |
| 2 | Models, Animal |
| 2 | Microscopy, Electron, Transmission |
| 2 | Microbial Viability |
| 2 | Medicine, Chinese Traditional |
| 2 | Masks |
| 2 | Machine Learning |
| 2 | Macau (epidemiology) |
| 2 | Lung Neoplasms (therapy) |
| 2 | Lung Neoplasms (diagnosis) |
| 2 | Lopinavir |
| 2 | Leukocyte Count |
| 2 | Latin America (epidemiology) |
| 2 | Japan (epidemiology) |
| 2 | International Health Regulations |
| 2 | International Cooperation |
| 2 | Intensive Care Units, Neonatal |
| 2 | Inpatients |
| 2 | Influenza, Human |
| 2 | Influenza, Human (diagnosis) |
| 2 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 2 | Immunity |
| 2 | Hospitals |
| 2 | Hospitals, Psychiatric |
| 2 | Hospitalization (statistics & numerical data) |
| 2 | Holidays |
| 2 | Health Workforce |
| 2 | Health Personnel (psychology) |
| 2 | Global Health (standards) |
| 2 | Germany |
| 2 | Genetic Variation |
| 2 | Genetic Engineering |
| 2 | Fever (epidemiology) |
| 2 | Feces (virology) |
| 2 | Feasibility Studies |
| 2 | Fear |
| 2 | Eutheria (virology) |
| 2 | European Union |
| 2 | Europe |
| 2 | Epitopes, T-Lymphocyte (immunology) |
| 2 | Epitopes, B-Lymphocyte (immunology) |
| 2 | Epithelial Cells (virology) |
| 2 | Epidemiological Monitoring |
| 2 | Emergency Service, Hospital |
| 2 | Emergency Medical Services |
| 2 | Editorial Policies |
| 2 | Drugs, Chinese Herbal |
| 2 | Drugs, Chinese Herbal (therapeutic use) |
| 2 | Disease Outbreaks (statistics & numerical data) |
| 2 | Developing Countries |
| 2 | Depression (epidemiology) |
| 2 | Decision Making |
| 2 | Critical Illness |
| 2 | Critical Care (standards) |
| 2 | Counseling |
| 2 | Cough (epidemiology) |
| 2 | Coronavirus Infections (metabolism) |
| 2 | Coronavirus (classification) |
| 2 | Communicable Disease Control (methods) |
| 2 | Commerce |
| 2 | Colorectal Neoplasms (therapy) |
| 2 | Cluster Analysis |
| 2 | Chloroquine (therapeutic use) |
| 2 | Chloroquine (pharmacology) |
| 2 | Chloroquine (analogs & derivatives) |
| 2 | Chlorocebus aethiops |
| 2 | Centers for Disease Control and Prevention, U.S. |
| 2 | Cell Line |
| 2 | Bronchoalveolar Lavage Fluid (virology) |
| 2 | Brazil |
| 2 | Blood Chemical Analysis |
| 2 | Biomedical Research (trends) |
| 2 | Biomarkers (blood) |
| 2 | Binding Sites |
| 2 | Betacoronavirus (ultrastructure) |
| 2 | Base Sequence |
| 2 | Anxiety (epidemiology) |
| 2 | Antiviral Agents (supply & distribution) |
| 2 | Antibodies, Viral (immunology) |
| 2 | Antibodies, Neutralizing (therapeutic use) |
| 2 | Anti-Bacterial Agents (therapeutic use) |
| 2 | Alphacoronavirus (genetics) |
| 2 | Algorithms |
| 2 | Alanine (pharmacology) |
| 2 | Airports |
| 2 | Africa (epidemiology) |
| 2 | Adrenal Cortex Hormones (therapeutic use) |
| 2 | Adenosine Monophosphate (therapeutic use) |
| 2 | Adenosine Monophosphate (analogs & derivatives) |
| 1 | outbreak |
| 1 | open source |
| 1 | oil price |
| 1 | hackathons |
| 1 | economic policy uncertainty |
| 1 | biohackers |
| 1 | announcement effect |
| 1 | Zoonoses (diagnosis) |
| 1 | Zika Virus |
| 1 | Zika Virus Infection (transmission) |
| 1 | Xenophobia (prevention & control) |
| 1 | Writing |
| 1 | Workflow |
| 1 | Whole Genome Sequencing (methods) |
| 1 | Web Browser (trends) |
| 1 | Web Browser (statistics & numerical data) |
| 1 | Weather |
| 1 | Water-Electrolyte Balance |
| 1 | Watchful Waiting |
| 1 | Waste Management (methods) |
| 1 | Voluntary Health Agencies |
| 1 | Vitamins (therapeutic use) |
| 1 | Virus Replication (drug effects) |
| 1 | Virus Physiological Phenomena |
| 1 | Virus Internalization |
| 1 | Virus Diseases (virology) |
| 1 | Virus Diseases (drug therapy) |
| 1 | Virus Attachment |
| 1 | Virus Attachment (drug effects) |
| 1 | Virus Activation |
| 1 | Virology (trends) |
| 1 | Viral Vaccines |
| 1 | Viral Vaccines (supply & distribution) |
| 1 | Viral Vaccines (adverse effects) |
| 1 | Viral Vaccines (administration & dosage) |
| 1 | Viral Tropism |
| 1 | Viral Structural Proteins (physiology) |
| 1 | Viral Proteins (metabolism) |
| 1 | Viral Nonstructural Proteins |
| 1 | Viral Nonstructural Proteins (physiology) |
| 1 | Viral Envelope Proteins |
| 1 | Viral Envelope Proteins (immunology) |
| 1 | Viral Envelope Proteins (genetics) |
| 1 | Video Recording |
| 1 | Veterinary Medicine (methods) |
| 1 | Veterinarians (psychology) |
| 1 | Vaccination |
| 1 | VIX |
| 1 | Truth Disclosure |
| 1 | Triage |
| 1 | Treatment Refusal |
| 1 | Treatment Outcome |
| 1 | Travel (statistics & numerical data) |
| 1 | Travel (economics) |
| 1 | Transportation (statistics & numerical data) |
| 1 | Trace Elements (therapeutic use) |
| 1 | Tongue (virology) |
| 1 | Tongue (metabolism) |
| 1 | Tomography, X-Ray Computed (standards) |
| 1 | Tomography, X-Ray Computed (methods) |
| 1 | Thorax |
| 1 | Thoracic Surgical Procedures |
| 1 | Teaching |
| 1 | TNF Receptor-Associated Factor 6 |
| 1 | Switzerland (epidemiology) |
| 1 | Students (psychology) |
| 1 | Stress, Psychological (therapy) |
| 1 | State Medicine (organization & administration) |
| 1 | Spouses |
| 1 | Spike Glycoprotein, Coronavirus |
| 1 | Spike Glycoprotein, Coronavirus (drug effects) |
| 1 | South America (epidemiology) |
| 1 | Solubility |
| 1 | Societies, Medical |
| 1 | Social Stigma |
| 1 | Social Media (trends) |
| 1 | Social Media (statistics & numerical data) |
| 1 | Social Isolation |
| 1 | Social Distance |
| 1 | Social Discrimination |
